EMA Authorised: Rybrevant (amivantamab) — Janssen-Cilag International N.V.

View source ↗

Summary

EMA authorised Rybrevant (amivantamab) for non-small cell lung cancer. The marketing authorization holder is Janssen-Cilag International N.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Janssen-Cilag International N.V.. Decision date: 18/09/2025